Lupus Science and Medicine (Mar 2024)
O33 Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis
Abstract
No abstracts available.
Lupus Science and Medicine (Mar 2024)